Literature DB >> 9566783

Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD).

C Roozendaal1, M H Zhao, G Horst, C M Lockwood, J H Kleibeuker, P C Limburg, G F Nelis, C G Kallenberg.   

Abstract

In IBD, the target antigens of anti-neutrophil cytoplasmic autoantibodies (ANCA) have not been fully identified, which limits the analysis of the diagnostic significance as well as of the possible pathophysiological role of these antibodies. In this study, we identify the target antigens of ANCA in large groups of patients with ulcerative colitis (UC) and Crohn's disease (CD). Apart from antibodies against lactoferrin and bactericidal/permeability-increasing protein (BPI), which have been reported before, antibodies against two novel granulocyte antigens were identified: antibodies against a 57/56-kD doublet were found in 38% of samples from UC patients and in 26% of samples from CD patients, whereas antibodies against a 47-kD protein were found in 10% of samples from UC patients and in 18% of samples from CD patients. Partial purification and amino acid sequence analysis identified the 57-kD protein as catalase and the 47-kD protein as alpha-enolase. This study is the first to report catalase and alpha-enolase as granulocyte antigens for autoantibodies in IBD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566783      PMCID: PMC1904946          DOI: 10.1046/j.1365-2249.1998.00528.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  beta-Glucuronidase antibodies in ulcerative colitis.

Authors:  L Nässberger; A Ljungh; G Schumacher; B Kollberg
Journal:  Lancet       Date:  1992-09-19       Impact factor: 79.321

2.  In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis.

Authors:  J Rosenfeld; J Capdevielle; J C Guillemot; P Ferrara
Journal:  Anal Biochem       Date:  1992-05-15       Impact factor: 3.365

3.  Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2.

Authors:  J Sobajima; S Ozaki; F Osakada; H Uesugi; H Shirakawa; M Yoshida; K Nakao
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

Review 4.  Catalase: Physical and chemical properties, mechanism of catalysis, and physiological role.

Authors:  A Deisseroth; A L Dounce
Journal:  Physiol Rev       Date:  1970-07       Impact factor: 37.312

5.  A gas-liquid solid phase peptide and protein sequenator.

Authors:  R M Hewick; M W Hunkapiller; L E Hood; W J Dreyer
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

6.  Antibodies to cathepsin G in Crohn's disease.

Authors:  W J Mayet; E Hermann; J Finsterwalder; H Rieder; T Poralla; K H Meyer Zum Büschenfelde
Journal:  Eur J Clin Invest       Date:  1992-06       Impact factor: 4.686

7.  Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.

Authors:  R S Walmsley; M H Zhao; M I Hamilton; A Brownlee; P Chapman; R E Pounder; A J Wakefield; C M Lockwood
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

8.  Purification of human granulocyte catalase in chronic myeloid leukemia.

Authors:  T Olofsson; I Olsson
Journal:  Biochim Biophys Acta       Date:  1977-06-10

9.  Interference of Wegener's granulomatosis autoantibodies with neutrophil Proteinase 3 activity.

Authors:  B A van de Wiel; K M Dolman; C H van der Meer-Gerritsen; C E Hack; A E von dem Borne; R Goldschmeding
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

Review 10.  Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders.

Authors:  C G Kallenberg; A H Mulder; J W Tervaert
Journal:  Am J Med       Date:  1992-12       Impact factor: 4.965

View more
  24 in total

Review 1.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

3.  Externalized glycolytic enzymes are novel, conserved, and early biomarkers of apoptosis.

Authors:  David S Ucker; Mohit Raja Jain; Goutham Pattabiraman; Karol Palasiewicz; Raymond B Birge; Hong Li
Journal:  J Biol Chem       Date:  2012-01-18       Impact factor: 5.157

4.  Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN).

Authors:  H Wakui; H Imai; A Komatsuda; A B Miura
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 5.  The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.

Authors:  Hendrik Schultz; Jerrold P Weiss
Journal:  Clin Chim Acta       Date:  2007-07-13       Impact factor: 3.786

6.  The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy.

Authors:  Agnieszka Magrys; Thimmappa Anekonda; Gaoying Ren; Grazyna Adamus
Journal:  J Clin Immunol       Date:  2007-01-19       Impact factor: 8.317

7.  Chemical unfolding of enolase from Saccharomyces cerevisiae exhibits a three-state model.

Authors:  Dénison S Sánchez-Miguel; Jahir Romero-Jiménez; César A Reyes-López; Ana Lilia Cabrera-Avila; Normande Carrillo-Ibarra; Claudia G Benítez-Cardoza
Journal:  Protein J       Date:  2010-01       Impact factor: 2.371

8.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease.

Authors:  Jan G M C Damoiseaux; Bas Bouten; Annick M L W Linders; Jos Austen; Caroline Roozendaal; Maurice G V M Russel; Pierre-Philippe Forget; Jan Willem Cohen Tervaert
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

9.  Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.

Authors:  Jason M God; Dan Zhao; Christine A Cameron; Shereen Amria; Jennifer R Bethard; Azizul Haque
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

10.  Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis.

Authors:  Bo Peng; Xueyong Huang; Ernesto S Nakayasu; John R Petersen; Suimin Qiu; Igor C Almeida; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2013-03-15       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.